Back to top
more

Iterum Therapeutics (ITRM)

(Delayed Data from NSDQ)

$1.57 USD

1.57
50,986

+0.02 (1.29%)

Updated Apr 25, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ITRM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Iterum Therapeutics PLC [ITRM]

Reports for Purchase

Showing records 1 - 20 ( 68 total )

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 1

03/14/2024

Daily Note

Pages: 1

Fireside Chat

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 2

03/06/2024

Daily Note

Pages: 3

Sulopenem uUTI NDA Resubmission Pulled Forward to First Half of 2Q24; Cash Runway Extends Into 2025; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 3

02/07/2024

Company Report

Pages: 9

Phase 3 REASSURE uUTI Study Is a Resounding Success; NDA Resubmission in 2Q24; Upgrading to Buy with $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 4

11/15/2023

Company Report

Pages: 7

3Q Recap; REASSURE Top-Line Data Readout in Early 1Q24 to Determine Sulopenem''s Path Forward; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 5

10/25/2023

Daily Note

Pages: 3

REASSURE Completes Enrollment; Sulopenem''s NDA Resubmission For uUTI Expected in 2Q24; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 6

08/18/2023

Company Report

Pages: 7

2Q Recap; Phase 3 REASSURE uUTI Study Now 50% Enrolled; Top-line Data Now Expected in 2Q24; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 7

05/18/2023

Company Report

Pages: 8

1Q Recap; Pivotal Phase 3 uUTI Study on Target For Complete Enrollment in 1H24; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 8

03/28/2023

Company Report

Pages: 7

4Q Recap; Top-line Data From REASSURE Study in Mid-2024 Assumes No Adjustments at Interim Analysis; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 9

11/11/2022

Company Report

Pages: 7

3Q Recap; Phase 3 REASSURE Sulopenem uUTI Study Begins; Composition Patent Extends IP to 2039; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 10

10/21/2022

Company Report

Pages: 6

New Phase 3 REASSURE Trial of Sulopenem in uUTI Initiated; NDA Resubmission Expected in 2H24; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 11

09/21/2022

Daily Note

Pages: 3

Sulopenem U.S. IP Protection Extends to 2039; New Phase 3 Study to Begin Enrollment Within Weeks; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 12

08/15/2022

Company Report

Pages: 7

2Q Recap; New Sulopenem Pivotal uUTI Study''s Initiation On Target in 4Q22; Awaiting Firmer Timeline; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 13

07/12/2022

Daily Note

Pages: 3

FDA Agrees to New Phase 3 Study of Oral Sulopenem Under a SPA; Trial Initiation Expected in 4Q22; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 14

05/16/2022

Company Report

Pages: 6

1Q Recap; Awaiting Details of New Phase 3 Trial of Sulopenem For uUTI; Cash Runway Extends Into 2024; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 15

05/11/2022

Daily Note

Pages: 3

We Await Further Details From Encouraging FDA Update; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 16

03/29/2022

Company Report

Pages: 7

4Q Recap: Initiation of New Pivotal Study of Sulopenem in uUTI Delayed to 2H22; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 17

11/15/2021

Company Report

Pages: 7

3Q Recap; Type B Meeting With FDA Around YE21; New Phase 3 uUTI Trial Start Expected in 1H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 18

10/11/2021

Industry Report

Pages: 8

IDWeek 2021: Poster Presentation Highlights Within Our Antibiotics Coverage Space

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 19

09/29/2021

Daily Note

Pages: 3

Type A Meeting Offers Path Forward for Sulopenem via New Phase 3 Study; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 20

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ITRM

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party